mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

COVID19 Clinical Trial

— TACTIC-R  

Official title:

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04390464
• Other study ID #: TACTIC-R
• Status: Recruiting
• Phase: Phase 4
• Start date: May 8, 2020
• Est. completion date: May 1, 2022

Study information

• Verified date: May 2020
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: Elena Hernan-Sancho
• Phone: 01223 349132
• Email: elena.hernansancho[@]addenbrookes.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID19 appears to be due to a later, exaggerated, host immune response. This leads to lung and sometimes multi-organ damage.

Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. Therefore, this study proposes to assess the efficacy of immunomodulatory agents that target dysregulated immune response that drive the severe lung, and other organ, damage. The medications investigated for efficacy in this trial are Baricitinib and Ravulizumab.

Description:

TACTIC-R will assess the efficacy of the immunomodulatory agents Baricitinib and Ravulizumab as potential treatments for COVID-19 disease against Standard of Care alone. These agents target the dysregulated immune response that drives the severe lung, and other organ, damage frequently seen during COVID-19 infection. This trial will compare these immunomodulatory agents to Standard of Care over a 14-day treatment period, with follow-up at 28 and 90 days. Patients will be randomised in a 1:1:1 ratio across treatments.

TACTIC-R will use a platform design with interim analysis to make efficient decisions about efficacy and futility (e.g. lack of efficacy and risk of harm) of the trial treatments. This enables the trial to stop recruiting to arms early where a clear efficacy decision can be made. It also allows for the addition of further arms.

TACTIC-R will also iterate an algorithm for use of clinical and biochemical phenotyping to:

1. Stratify patients to therapeutic arms according to probability of efficacy

2. Identify early indicators of failure of therapeutic strategy.

By collecting samples for genomics, transcriptomics, proteomics and immunological phenotyping, parallel studies associated with TACTIC-R will investigate host susceptibility factors for development of severe COVID-19-related disease and predictive biomarkers of response to therapeutic strategy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1167
• Est. completion date: May 1, 2022
• Est. primary completion date: May 7, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

To be included in the trial the participant must:

1. Be aged 18 and over

2. Have clinical picture strongly suggestive of COVID-19-related (with/without positive COVID-19 test) AND

• Risk count (as defined below) >3 OR

• = 3 if risk count includes "Radiographic severity score >3"

3. Be considered an appropriate subject for intervention with immunomodulatory in the opinion of the supervising clinician

4. Be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines

Exclusion Criteria

The presence of any of the following will preclude participant inclusion:

1. Inability to supply direct informed consent or assent from Next of Kin or Independent Healthcare Provider on behalf of patient

2. Mechanical ventilation at time of prior to dosing

3. Contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients

4. Currently on any of the study investigational medicinal products

5. Known unresolved Neisseria meningitidis infection

6. Unwilling to be vaccinated against Neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination

7. Known active tuberculosis (no blood screening required)

8. Known active Hepatitis B or C (no blood screening required); active varicella zoster

9. Concurrent participation in any interventional clinical trial including COVID-19-related disease trials (observational studies allowed)

10. Patient moribund at presentation or screening

11. Pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol)

12. Unwillingness to adhere to breastfeeding advice in protocol

13. Either alanine transaminase or aspartate transaminase (ALT or AST) > 5 times the upper limit of normal

14. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. Cockcroft Gault estimated creatinine clearance < 30 ml /min/1.73 m^2)

15. Currently receiving probenecid or chronic IVIG treatment

16. Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern.

Risk Count

Patients will be given a Risk Count equal to the cumulative points received for the following criteria (no = 0 points, yes = 1 point):

Male gender, Age > 40 years, Non-white ethnicity, Diabetes, Hypertension, Neutrophils > 8.0x10^9/L, CRP > 40mg/L, Radiographic severity score >3

Related Conditions & MeSH terms

• COVID19

Intervention

Drug:
• Ravulizumab
Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
• Baricitinib
Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.

Other:
• Standard of care
Regular standard of care for COVID-19 patients

Locations

Country	Name	City	State
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge	Cambridgeshire

Sponsors (1)

Lead Sponsor	Collaborator
Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure	Number of days taken for occurrence of one of the following events: 1. Death 2. Mechanical ventilation 3. Extracorporeal membrane oxygenation (ECMO) 4. Cardiovascular organ support (balloon pump or inotropes) 5. Renal failure (estimated creatinine clearance (by Cockcroft-Gault formula) <15 ml /min/1.73m^2), haemofiltration or dialysis	up to Day 14
Secondary	Change in clinical status as assessed on 7-point ordinal scale compared to baseline	The clinical status of the patients is assessed using 7-point ordinal scale as follows: 1 = Death, 2 = Mechanical ventilation, 3 = Non-invasive or high flow oxygen, 4 = Low flow oxygen, 5 = Hospitalised - no oxygen, 6 = Discharged - normal activities not resumed, 7 = Discharged - normal activities resumed	14 days
Secondary	Proportion of patients with adverse events of special interest in each treatment arm	The proportion of patients in each treatment arm that experience adverse events of special interest, defined as: venous thromboembolism, new infections requiring antimicrobials	14 days
Secondary	Time to Sp02 >94% on room air	The time taken to achieve blood oxygen saturation levels above 94% in patients on room air, measured in hours/days	14 days
Secondary	Time to first negative SARS-CoV2 PCR	The amount of time between a patient's first positive SARS-CoV2 PCR test and a patient's first negative SARS-CoV2 PCR test, measured in days	14 days
Secondary	Duration of oxygen therapy	The duration of oxygen therapy given to a patient, measured in days	14 days
Secondary	Duration of hospitalisation	The duration of hospitalisation of a patient, measured in days	14 days
Secondary	All cause mortality at day 28	The number of deaths recorded at 28 days irrespective of the cause	28 Days
Secondary	Time to clinical improvement	The time to clinical improvement for a patient, defined as: >2 point improvement from Day 1 on the 7-point ordinal scale, measured in days	14 days